226 related articles for article (PubMed ID: 37863846)
1. Novel therapeutic perspectives in Noonan syndrome and RASopathies.
Saint-Laurent C; Mazeyrie L; Yart A; Edouard T
Eur J Pediatr; 2024 Mar; 183(3):1011-1019. PubMed ID: 37863846
[TBL] [Abstract][Full Text] [Related]
2. The RASopathies: from pathogenetics to therapeutics.
Hebron KE; Hernandez ER; Yohe ME
Dis Model Mech; 2022 Feb; 15(2):. PubMed ID: 35178568
[TBL] [Abstract][Full Text] [Related]
3. New prospectives on treatment opportunities in RASopathies.
Gelb BD; Yohe ME; Wolf C; Andelfinger G
Am J Med Genet C Semin Med Genet; 2022 Dec; 190(4):541-560. PubMed ID: 36533679
[TBL] [Abstract][Full Text] [Related]
4. An Assessment of the Therapeutic Landscape for the Treatment of Heart Disease in the RASopathies.
Yi JS; Perla S; Bennett AM
Cardiovasc Drugs Ther; 2023 Dec; 37(6):1193-1204. PubMed ID: 35156148
[TBL] [Abstract][Full Text] [Related]
5. Autism traits in the RASopathies.
Adviento B; Corbin IL; Widjaja F; Desachy G; Enrique N; Rosser T; Risi S; Marco EJ; Hendren RL; Bearden CE; Rauen KA; Weiss LA
J Med Genet; 2014 Jan; 51(1):10-20. PubMed ID: 24101678
[TBL] [Abstract][Full Text] [Related]
6. Rare variants in SOS2 and LZTR1 are associated with Noonan syndrome.
Yamamoto GL; Aguena M; Gos M; Hung C; Pilch J; Fahiminiya S; Abramowicz A; Cristian I; Buscarilli M; Naslavsky MS; Malaquias AC; Zatz M; Bodamer O; Majewski J; Jorge AA; Pereira AC; Kim CA; Passos-Bueno MR; Bertola DR
J Med Genet; 2015 Jun; 52(6):413-21. PubMed ID: 25795793
[TBL] [Abstract][Full Text] [Related]
7. Molecular and clinical profile of patients referred as Noonan or Noonan-like syndrome in Greece: a cohort of 86 patients.
Papadopoulos G; Papadopoulou A; Kosma K; Papadimitriou A; Papaevangelou V; Kanaka-Gantenbein C; Bountouvi E; Kitsiou-Tzeli S
Eur J Pediatr; 2022 Oct; 181(10):3691-3700. PubMed ID: 35904599
[TBL] [Abstract][Full Text] [Related]
8. [Update on the treatment of RASopathies].
Duat-Rodriguez A; Hernandez-Martin A
Rev Neurol; 2017 May; 64(s03):S13-S17. PubMed ID: 28524213
[TBL] [Abstract][Full Text] [Related]
9. Succesful MEK-inhibition of severe hypertrophic cardiomyopathy in RIT1-related Noonan Syndrome.
Leegaard A; Gregersen PA; Nielsen TØ; Bjerre JV; Handrup MM
Eur J Med Genet; 2022 Nov; 65(11):104630. PubMed ID: 36184070
[TBL] [Abstract][Full Text] [Related]
10. Molecular Genetics of Noonan Syndrome and RASopathies.
Liao J; Mehta L
Pediatr Endocrinol Rev; 2019 May; 16(Suppl 2):435-446. PubMed ID: 31115195
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in RASopathies.
Aoki Y; Niihori T; Inoue S; Matsubara Y
J Hum Genet; 2016 Jan; 61(1):33-9. PubMed ID: 26446362
[TBL] [Abstract][Full Text] [Related]
12. Craniosynostosis in patients with RASopathies: Accumulating clinical evidence for expanding the phenotype.
Ueda K; Yaoita M; Niihori T; Aoki Y; Okamoto N
Am J Med Genet A; 2017 Sep; 173(9):2346-2352. PubMed ID: 28650561
[TBL] [Abstract][Full Text] [Related]
13. The RASopathies.
Rauen KA
Annu Rev Genomics Hum Genet; 2013; 14():355-69. PubMed ID: 23875798
[TBL] [Abstract][Full Text] [Related]
14. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation.
Tidyman WE; Rauen KA
Curr Opin Genet Dev; 2009 Jun; 19(3):230-6. PubMed ID: 19467855
[TBL] [Abstract][Full Text] [Related]
15. Enhanced MAPK1 Function Causes a Neurodevelopmental Disorder within the RASopathy Clinical Spectrum.
Motta M; Pannone L; Pantaleoni F; Bocchinfuso G; Radio FC; Cecchetti S; Ciolfi A; Di Rocco M; Elting MW; Brilstra EH; Boni S; Mazzanti L; Tamburrino F; Walsh L; Payne K; Fernández-Jaén A; Ganapathi M; Chung WK; Grange DK; Dave-Wala A; Reshmi SC; Bartholomew DW; Mouhlas D; Carpentieri G; Bruselles A; Pizzi S; Bellacchio E; Piceci-Sparascio F; Lißewski C; Brinkmann J; Waclaw RR; Waisfisz Q; van Gassen K; Wentzensen IM; Morrow MM; Álvarez S; Martínez-García M; De Luca A; Memo L; Zampino G; Rossi C; Seri M; Gelb BD; Zenker M; Dallapiccola B; Stella L; Prada CE; Martinelli S; Flex E; Tartaglia M
Am J Hum Genet; 2020 Sep; 107(3):499-513. PubMed ID: 32721402
[TBL] [Abstract][Full Text] [Related]
16. The seventh international RASopathies symposium: Pathways to a cure-expanding knowledge, enhancing research, and therapeutic discovery.
Kontaridis MI; Roberts AE; Schill L; Schoyer L; Stronach B; Andelfinger G; Aoki Y; Axelrad ME; Bakker A; Bennett AM; Broniscer A; Castel P; Chang CA; Cyganek L; Das TK; den Hertog J; Galperin E; Garg S; Gelb BD; Gordon K; Green T; Gripp KW; Itkin M; Kiuru M; Korf BR; Livingstone JR; López-Juárez A; Magoulas PL; Mansour S; Milner T; Parker E; Pierpont EI; Plouffe K; Rauen KA; Shankar SP; Smith SB; Stevenson DA; Tartaglia M; Van R; Wagner ME; Ware SM; Zenker M
Am J Med Genet A; 2022 Jun; 188(6):1915-1927. PubMed ID: 35266292
[TBL] [Abstract][Full Text] [Related]
17. RASopathies and cardiac manifestations.
Hilal N; Chen Z; Chen MH; Choudhury S
Front Cardiovasc Med; 2023; 10():1176828. PubMed ID: 37529712
[TBL] [Abstract][Full Text] [Related]
18. Mosaic RASopathies: A review of disorders caused by somatic pathogenic variants in the genes of the RAS/MAPK pathway.
Carli D; Resta N; Ferrero GB; Ruggieri M; Mussa A
Am J Med Genet C Semin Med Genet; 2022 Dec; 190(4):520-529. PubMed ID: 36461154
[TBL] [Abstract][Full Text] [Related]
19. Malignancy in Noonan syndrome and related disorders.
Smpokou P; Zand DJ; Rosenbaum KN; Summar ML
Clin Genet; 2015 Dec; 88(6):516-22. PubMed ID: 25683281
[TBL] [Abstract][Full Text] [Related]
20. Copy number variants and rasopathies: germline KRAS duplication in a patient with syndrome including pigmentation abnormalities.
Gilbert-Dussardier B; Briand-Suleau A; Laurendeau I; Bilan F; Cavé H; Verloes A; Vidaud M; Vidaud D; Pasmant E
Orphanet J Rare Dis; 2016 Jul; 11(1):101. PubMed ID: 27450488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
